Nanoscale engagement and clusterization of Programmed death ligand 1 (PD-L1) in the membrane lipid rafts of Non-Small Cell Lung Cancer cells
M. Ruglioni, S. Civita, T. Salvadori, S. Cristiani, V. Carnicelli, S. Barachini, I. Petrini, I. Nepita, M. Castello, A. Diaspro, P. Bianchini, B. Storti, R. Bizzarri, S. Fogli, R. Danesi
Abstract
Programmed death ligand 1 (PD-L1) plays a key role in several human tumors, and it has recently become a crucial target for cancer therapy. Yet, its subtle regulatory roles beside the well characterized immunosuppression in PD-1/PD-L1 immune checkpoint are still obscure and should be strictly related to its molecular properties in different cell settings. In this study we targeted the plasma membrane organization of PD-L1 in a Non-Small Cell Lung Cancer (NSCLC) cell line by a multiscale fluorescence imaging toolbox that included super-resolution microscopy approaches to reach the nanoscale. Our findings revealed for the first time that PD-L1 is prevalently engaged in the cholesterol-enriched "raft" regions of the cell membrane. Clusterization and engagement in membrane rafts may afford novel targets for the immuno-oncology strategies in the framework of NSCLC and, possibly, other tumor types.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiple mechanisms regulate the nanoscale organization of PD-L1 at the cell surface
Guus A. Franken, Abbey B. Arp, … Annemiek B. van Spriel·bioRxiv·Aug 31, 2026
- Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion
S. Zhang, H.-Y. Wang, … X. Lin·bioRxiv·Oct 17, 2021
- Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
- Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells.
A. Letian, E. Y. Lemma, … T. E. McGraw·bioRxiv·Sep 17, 2021
- Detection of PD-L1-expressing myeloid cell clusters in the hyaluronan-enriched stroma in tumor tissue and tumor-draining lymph nodes
P. R. Dominguez-Gutierrez, E. Kwenda, … S. Kusmartsev·bioRxiv·Dec 15, 2020
- CD4 T cell surface architecture is associated with response to anti-PD-1 therapy in non-small cell lung cancer
Riccardo Cinotti, Ying Yang, … Andreas Lundqvist·bioRxiv·Oct 30, 2026